tldrdailynews.com logo

KRAS-targeting pill daraxonrasib nearly doubles survival in metastatic pancreatic cancer

1 min read
Source: BBC
KRAS-targeting pill daraxonrasib nearly doubles survival in metastatic pancreatic cancer
Photo: BBC
TL;DR Summary

A multinational trial with 500 patients shows the KRAS-targeting pill daraxonrasib nearly doubles median overall survival in advanced pancreatic cancer (13.2 months vs 6.6 months with chemotherapy), with fewer side effects, marking a potential breakthrough for KRAS-mutant tumors.

Topics:health#clinical-trial#daraxonrasib#health#kras#pancreatic-cancer#survival
Share this article
  1. Daily pill doubles survival time for pancreatic cancer patients  BBC
  2. After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses  NBC News
  3. ‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long  The Washington Post
  4. A standing ovation for RevMed, and caution for Akeso  statnews.com
  5. New drug nearly doubles survival rates in some pancreatic cancer patients, study says  CBS News

Reading Insights

Total Reads

0

Unique Readers

14

Time Saved

1 min

vs 2 min read

Condensed

82%

215 → 38 words

Want the full story? Read the original article

Read on BBC